A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

This is a Phase 1b/2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).

Trial Details

NCT ID
NCT05421663
Phase
PHASE1 / PHASE2
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Prizloncabtagene autoleucel (Prizlo-Cel)
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Denver, Colorado, United States|39.73915,-104.9847
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Lexington, Kentucky, United States|37.98869,-84.47772
  • Piscataway, New Jersey, United States|40.49927,-74.39904

Key Eligibility Criteria

  • Participant must be greater than or equal to (\>=) 18 years of age, at the time of signing informed consent
  • Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20 positive
  • Must meet the indications for each subtype in Phase 1b as specified in protocol and Phase 2 participants must have following: Diagnosis of Large B-…
  • Measurable disease as defined by Lugano 2014 classification

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →